HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael P. Siegenthaler Jack A. Roth Stephen G. Swisher Garrett L. Walsh Ara A. Vaporciyan W. Roy Smythe Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegenthaler, M. P. Articles by Putnam, J. B. Search for Related Content PubMed PubMed Citation Articles by Siegenthaler, M. P. Articles by Putnam, J. B., Jr Related Collections Lung - cancer

Ann Thorac Surg 2001;71:1105-1112
© 2001 The Society of Thoracic Surgeons

---

Original article: general thoracic

Preoperative chemotherapy for lung cancer does not increase surgical morbidity

^a Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
^b Department of Thoracic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

Address reprint requests to Dr Putnam, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 109, Houston, TX 77030
e-mail: putnam{at}mdanderson.org

Presented at the Thirty-sixth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 31–Feb 2, 2000.

	Abstract

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
Background. Preoperative chemotherapy (C+S) for non–small cell lung cancer (NSCLC) has increased in an attempt to improve survival. Patients receiving C+S potentially may have an increase in postoperative morbidity and mortality compared with surgery alone (S). We reviewed our experience with C+S and S in a tertiary referral center.

Methods. Three hundred eighty consecutive patients underwent lobectomy or greater resection for NSCLC between August 1, 1996, and April 30, 1999: 335 patients (259 S; 76 C+S) were analyzed; 45 additional patients were excluded for prior NSCLC, other chemotherapy for other malignancy, or radiation. We compared morbidity and mortality overall, and by subset analysis (clinical stage, pathological stage, procedure, and by protocol use) for both C+S and S patients.

Results. Demographics, comorbidities, and spirometry were similar. We noted no significant difference in overall or subset mortality or morbidity including pneumonia, acute respiratory distress syndrome, reintubation, tracheostomy, wound complications, or length of hospitalization.

Conclusions. C+S did not significantly affect morbidity or mortality overall, based on clinical stage, postoperative stage, or extent of resection. The potential for enhanced survival in resectable NSCLC justifies continued study of C+S.

	Introduction

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
Lung cancer remains a significant public health problem in the United States with an estimated 171,600 new cases in 1999; 158,900 of those will eventually die from this disease [1]. However, even in its earliest stages, which are amenable to surgical resection, survival after complete resection is compromised by local and systemic recurrences [2, 3]. Survival is poor (0% to 10% at 5 years) for patients with advanced stage non–small cell lung cancer (NSCLC) (stages III and IV) [3].

To improve survival, multiple studies have explored the role of adjuvant therapies including pre- and postoperative chemotherapy and radiation for NSCLC. After disappointing results of postoperative chemotherapy with no improvement in survival [4, 5], most clinical trials in the past decade have explored preoperative chemotherapy or chemoradiation therapy to enhance local and systemic therapy in advanced stage (IIIA) lung cancer. Two small (single institution) prospective randomized trials showed benefit of this approach in stage IIIA NSCLC [6, 7]. However, several reports [8–11] have reported significant surgical morbidity and mortality associated with preoperative treatment.

We examined the influence of preoperative chemotherapy on surgical outcomes by comparing patients receiving preoperative chemotherapy (C+S) with patients undergoing surgery alone (S).

	Patients and methods

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
We reviewed 380 consecutive patients undergoing anatomic pulmonary resection (lobectomy or greater) for NSCLC between August 1, 1996, and April 30, 1999. Forty-five anatomic resections were excluded from the analysis for a history of a prior lung cancer (n = 21), prior chest radiation or chemoradiation therapy for positive N2 nodes (n = 17), or history of any malignancy other than nonmelanoma skin cancer within the past year (n = 7). During this same time, an additional 140 segmentectomies and other nonanatomic resections for NSCLC were performed (generally in high-risk patients) and not included in the analysis. Our study population included 335 patients: 259 patients had surgery alone (S) and 76 patients had preoperative chemotherapy (C+S).

Data acquisition
Beginning in August 1996, we concurrently collected postoperative events (eg, any event that had an impact on the patient’s convalescence or treatment) and stored them electronically. At the time of discharge, the physician caring for the patient completed a scannable data sheet to record postoperative events. These events included pulmonary, cardiac, gastrointestinal, blood usage, wound infections, other wound problems, and other events. All database elements were prospectively defined within a database dictionary for consistency of data collection. These definitions allowed for a more precise use of clinical terms such as "adult respiratory distress syndrome" (ARDS) or "pneumonia," which are used differently by many authors [12–16]. The collected data were reviewed monthly at our quality assurance (morbidity and mortality) conference. Data validity and quality was controlled at this conference by review of the physicians responsible for each patient’s care and by periodic selective randomized retrospective chart audits. All of the end points in this study were derived from this database. None of the end points was collected retrospectively.

Patients’ preoperative comorbidities were collected retrospectively by one of us (M.P.S.). Pulmonary function values were collected from our database. The extent of surgical resection was obtained by review of the operative reports. Surgical mortality was defined as any death occurring within 30 days, or after 30 days if the patient was continuously hospitalized after surgery.

Preoperative treatment
Multiple chemotherapy agents were used. These chemotherapy agents and the administration of chemotherapy on a clinical protocol or in an "ad hoc" manner were recorded. Time intervals between the last dose of chemotherapy and surgery as well as the number of chemotherapy cycles were recorded.

Clinical and pathologic staging
Preoperative clinical staging (cStage) was based on all information before definitive resection. These information sources included the patients’ preoperative clinic notes, radiology reports, review of selected computed tomography scans of the chest and all invasive staging methods such as bronchoscopy, mediastinoscopy, needle biopsy, or other techniques. Patients who responded to preoperative treatment (disappearance of N2 nodes or regression of the primary tumor on computed tomography scan) were clinically "down-staged" based on imaging information alone.

The postoperative (pathologic) stage (pStage) was obtained from our departmental database. After review by a trained research nurse, final pathology stage was based on the final written pathology report and operative findings. Pathological stage was further reviewed and validated by the senior surgeon responsible for that patient. Patients with two histologically different, concurrent tumors (4 patients) were staged by the more advanced TNM status of the two tumors.

Data analysis
Differences between the C and C+S treatment groups were tested for significance by the ² test for categorical variables and the Student’s t test for continuous variables. The patients were analyzed by surgical procedure, cStage, pStage, and by chemotherapy given on a study protocol or in an "off protocol" setting. Statistical significance was defined as p less than 0.05. All statistical analyses were performed using SPSS software (SPSS Inc, Chicago, IL).

A logistic regression model was constructed with occurrence of a major complication as the dependent variable. Any hospital mortality, pneumonia, reintubation, tracheostomy, ARDS, empyema, bronchopleural fistula, wound complication, blood transfusion, readmit to hospital, or readmit to intensive care unit was defined as a major event. The other covariates included in the model were age, history of coronary artery disease, hypertension, or diabetes, preoperative treatment (chemotherapy versus no chemotherapy), pathologic stage (1,2 versus 3,4), and procedure (lobectomy, sleeve-resection, bilobectomy versus pneumonectomy).

	Results

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
Data quality
Departmental review at the quality assurance conference as well as selective randomized chart reviews validated and confirmed accuracy of recorded data.

Patient characteristics
The C+S and S alone groups had similar demographics (Table 1). The S group tended to be slightly older (median 65 versus 62.4 years, p = NS). Comorbidities, histology, and lung functions were also similar in both groups (Table 1). The stage distribution between the two groups was significantly different, with more early stage NSCLC (stages 1A, 1B) in the S group (p = 0.02).

	Comment

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
Preoperative treatment for advanced stage NSCLC has been evaluated in several phase 2 and 3 clinical trials [18–21]. These studies had acceptable treatment related complication rates. However, patient selection was restrictive and patients with significant comorbidities were likely to be excluded from these studies. Other studies reported a relatively high surgical morbidity and mortality after preoperative treatment [8–10]. These series reviewed a small number of patients who received preoperative combined modality chemoradiation treatment. An increased incidence of culture negative infiltrates (ARDS) and bronchopleural fistulas was found, mainly after pneumonectomy. Another recently published report found no increased incidence in these complications in 19 consecutive patients who all received combined modality therapy and definitive radiation of more than 59 Gy [22]. In this series all but 1 patient had carefully harvested intercostal flap coverage of the bronchial stump. The 1 patient without this flap developed a bronchopleural fistula. A recent abstract [11] retrospectively reviewed a small number of patients receiving only preoperative chemotherapy with carboplatin and paclitaxel and no concurrent radiation. A mortality rate of 8% and a 32% incidence of life-threatening complications were found. Our study did not confirm these findings. We analyzed all consecutive patients with NSCLC who had an anatomic lung resection and were operated on with curative intent. We excluded patients with recurrent NSCLC or history of another recent malignancy. No retrospectively collected end points were included in our analysis.

We compared those factors that are known to influence surgical morbidity, including age, spirometry results, type of surgical resection, diabetes, coronary artery disease, and hypertension. We found no differences in our two study populations (C+S and S alone). The study groups appear to be similar on retrospective review; however, only a prospective randomized trial allows for stratification of these variables. We did not measure other risk factors that may influence surgical outcomes, including current smoking status, nutritional status, surgical incision, type of postoperative pain control, or results of the surgeons. Sophisticated risk scoring systems have been developed in several surgical specialties such as in trauma, critical care, and cardiac surgery [23–26], and only recently such a risk scoring system has been tested for noncardiac thoracic surgery patients [27].

The preoperative side effects and complications of chemotherapy have been well documented in the two prospectively randomized controlled trials [6, 7]. Chemotherapy-related complications were also carefully reported in a recent phase 2 study for early stage NSCLC [17]. In this multicenter study of 94 patients, significant toxicity after preoperative paclitaxel and carboplatin included grade 3 to 4 neutropenia in 35% with no hospital admissions for febrile neutropenia. Also common were moderate (grade 2) myalgias and arthralgias in 26%. Most of these complications resolved within a week. More severe hematologic and neuromuscular complications were found in less than 5%. During induction chemotherapy in this study 1 patient (1%) died of a cerebrovascular accident while recovering from chemotherapy-induced toxicity, 96% of patients completed the preoperative chemotherapy, and 94% were operated on with intent to cure. Reasons for not undergoing an operation included disease progression (n = 3), loss to follow-up, unresectable status, or death in 1 patient each. Thirty-four of the 94 patients from that multicenter study were treated at our institution and included in our analysis. Morbidity induced by preoperative chemotherapy for early NSCLC appears to be acceptable. However, to further study this modality, a multi-institutional (phase III Intergroup) prospective randomized trial (SWOG S9900) is currently underway.

Patients in our study were not analyzed on an intent-to-treat basis. Only patients who underwent surgical resection were entered into our thoracic surgery database and analyzed. In contrast to advanced stage NSCLC [6, 7] there is currently no prospective evidence for a survival advantage after preoperative chemotherapy for stage 1 or 2 NSCLC; this treatment should be given only after informed consent in a protocol setting.

Given the intensity of chemotherapy combinations used, it appears surprising that no significant impact on surgical morbidity could be measured. Surgical outcomes were similar for patients if they were given chemotherapy on protocol or in an uncontrolled ad hoc setting, or if no chemotherapy was given. The number of patients in this series was large enough to measure surgical morbidity stratified by several risk groups, including clinical and pathological stage, extent of surgical resection, and protocol enrollment. Our study population and the number of events observed were not large enough to detect small differences in these surgical morbidities. A trend toward increased pulmonary morbidity in early stage lung cancers was noted in this study.

In summary, preoperative chemotherapy did not significantly affect morbidity or mortality overall, based on clinical or pathological stage, nor by the extent of the pulmonary resection performed. These data, coupled with the well-known preoperative side effects and complications of chemotherapy, justify continued study of preoperative chemotherapy for NSCLC.

	Acknowledgments

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
This work was supported in part by the Texas Tobacco Settlement Fund and the Charles and Beverly Adams Fund for Thoracic Surgery Research.

	Discussion

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 
DR JOHN C. WAIN (Boston, MA): I would like to thank Dr Siegenthaler and his colleagues for the opportunity to review this paper before its presentation.

I think they are to be commended on two points. They certainly have a lucid and well-documented presentation that demonstrates the immense utility of a real-time data collection system for outcome assessment in patients. A methodology as straightforward and simple as what they described here, which involves recording data about patients at the time of discharge, followed by validation at the weekly or monthly quality assurance conferences, or mortality and morbidity conferences, I think is really invaluable. Not only does the real-time data recording result in ready data for answering clinical questions such as the one posed by the article here, but it is also useful for systematic evaluations and improvements in patient care. Most importantly, perhaps, this is a study in which the methodology and the data were designed, implemented, and managed by the surgeons who were involved in the patient’s care. So that in fact if anyone has any questions about the data they can provide answers quickly and easily.

The second major point I would like to emphasize is that I think the surgical outcomes here are excellent, particularly as demonstrated by the low mortality rate of only 1.7% in patients undergoing lobectomy after preoperative chemotherapy, certainly answering the question posed by the tile of the paper.

I have only three questions for the authors:

1. What would be the indications for chemotherapy in the patients, particularly the early stage patients? I appreciate that some of the patients were on protocol and some were not, but I wondered how much subjectivity there might be in selecting those patients who did not receive chemotherapy, particularly the ones off protocol.
   
2. The low incidence of pneumonectomy in the preoperative chemotherapy group, particularly in the stage III-A group, is striking, and I was wondering if the authors have any indication that their preoperative chemotherapy in fact resulted in a downstaging to the extent that a resection less extensive than a pneumonectomy was possible?
   
3. And lastly, as the authors noted, there was a trend toward longer hospital stay and increased pulmonary morbidity, somewhat surprisingly, in the early stage group receiving chemotherapy, and I was wondering if they have any hypothesis as to why this might have happened whether it relates to factors not controlled for here, such as smoking or nutritional status, or other factors unique to chemotherapy such as the use of granulocyte colony-stimulating factor, which may induce inflammation in the lung in the postoperative period? And in view of this finding, would they recommend the concept of using chemotherapy in earlier stage lung cancers, which certainly seems to be a developing trend in the management of lung cancer, but perhaps should be rethought.
   

DR JOHN ROBERTS (Nashville, TN): I enjoyed your paper very much as well, and I had three quick questions.

First, I did not understand slide very well, but it appeared that you had a 4.5% mortality for the surgery-alone group. Is that true?

Second, fewer than 25% of your patients received preoperative chemotherapy. That surprises me for your institution. Do all of your III-A patients receive preoperative chemotherapy or do more of them go into chemoradiotherapy?

Finally, your data are at odds with the data that we presented at ASCO, and with the increased mortality that Elias found in the CALGB group study that was conducted a few years ago. I wondered if you had any comment about that?

DR MUHAMMAD MUMTAZ (Overland Park, KS): What was the protocol for chemotherapy and how much time did you wait before surgery? Did you have any patients that are not listed here that were initially going to have to go to a surgery arm but did not because of morbidity related to chemotherapy?

DR SIEGENTHALER: Thank you Dr Wain, for your kind comments and questions. I would like to start with your questions first.

What were the indications for chemotherapy? We tried to include every patient on our early stage protocol, which includes patients with stages 1b, 2a and b as well as the T3N1 group, which is a subgroup of stage 3a. This protocol is now available as the BLOT Intergroup trial. Every patient who is eligible and willing to participate in this trial gets enrolled. In all other patients, we would perform surgery alone. Only through a formal protocol can we determine a survival advantage.

Your second question addresses a possible down-staging effect, given the low incidence of pneumonectomy in the chemotherapy and surgery group. I think we have to be careful here. Our study group was fairly small. We also noted, when we correlated the clinical preoperative stage with the final postoperative stage, that there was a significant difference after preoperative chemotherapy. The chemotherapy group had a much higher number of patients that were down-staged, which again could be a sign of a treatment effect. The study population was too small and the patient selection was uncontrolled to make such a conclusion.

The third question was about the trend for an increased length of stay and pulmonary morbidity. I think there are uncontrolled factors, as you mentioned, which were not analyzed. An answer would be purely speculative. It might be a chemotherapy-associated effect. Ninety percent of our patients received Carboplatin and Taxol. The usual dose limiting toxicity for those agents is neuropathies and neurotoxicities, not bone marrow suppression. No routine growth factor support was used.

I think this also explains Dr Mumtaz’s first question. His second question was about the time interval between the surgery and chemotherapy. On the protocol, the surgery was usually performed 1 month after the last administration of chemotherapy. However, this was flexible if longer recovery from the chemotherapy was necessary. We collected the data about the timing between chemotherapy and surgery, but since we found no difference in the univariate analysis, we did not analyze the time interval further.

To Dr Robert’s questions, mortality was higher in the surgery alone group, most likely due to the higher number of patients receiving pneumonectomy. The mortality rate was 5%. We did not find the same morbidity associated with preoperative chemotherapy that you found in your previous investigation. I cannot explain this difference between our institutions although our study population was larger. Your last question was why only 25% of patients received chemotherapy. I think the overall proportion was higher. Patients receiving preoperative chemo-radiation for stage 3a were excluded from the analysis. A high proportion of our clinical stage 3a patients received preoperative treatment. For earlier stages, however, we do not believe that chemotherapy should be given in an "off protocol" setting, since there is no hard data proving a survival benefit for this patient group.

	References

Top Abstract Introduction Patients and methods Results Comment Acknowledgments Discussion References

 

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.[Abstract/Free Full Text]
2. Nesbitt J.C., Putnam J.B.J., Walsh G.L., Roth J.A., Mountain C.F. Survival in early-stage non–small cell lung cancer. Ann Thorac Surg 1995;60:466-472.[Abstract/Free Full Text]
3. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.[Abstract/Free Full Text]
4. Pisters K.M., Kris M.G., Gralla R.J., et al. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non–small cell lung cancer. J Surg Oncol 1994;56:236-241.[Medline]
5. Figlin R.A., Piantodosi S. A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non–small cell carcinoma of the lung. Chest 1994;106:310S-312S.[Abstract/Free Full Text]
6. Roth J.A., Fossella F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.[Abstract/Free Full Text]
7. Rosell R., Gomez-Codina J., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non–small-cell lung cancer. N Engl J Med 1994;330:153-158.[Abstract/Free Full Text]
8. Bonomi P., Faber L.P., Warren W., et al. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation. Semin Oncol 1997;24:S12.
9. Fowler W.C., Langer C.J., Curran W.J.J., Keller S.M. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993;55:986-989.[Abstract]
10. Deutsch M., Crawford J., Leopold K., et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non–small cell lung cancer. Cancer 1994;74:1243-1252.[Medline]
11. Roberts J.R., DeVore R.F., Carbone D.P., et al. Neoadjuvant chemotherapy increases perioperative complications in patients undergoing resection for NSCLC. Proc ASCO 2000;18:465A.
12. Bernard G.R., Artigas A., Brigham K.L., et al. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994;9:72-81.[Medline]
13. Schuster D.P. Identifying patients with ARDS: time for a different approach. Intensive Care Med 1997;23:1203.
14. Sachdeva R.C., Guntupalli K. Acute respiratory distress syndrome. Crit Care Clin 1997;13:503-521.[Medline]
15. Meduri G.U., Johnanson W.G. International Consensus Conference: clinical investigation of ventilator-associated pneumonia. Chest 1992;102:551S-552S.[Abstract/Free Full Text]
16. Pingleton S.K., Fagon J.Y., Leeper K.V. Patient selection for clinical investigation of ventilator-associated pneumonia. Chest 1992;105:553S-556S.
17. Pisters K.M., Ginsberg R.J., Giroux D.J., et al. Bimodality Lung Oncology Team (BLOT). Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000;119:429-439.[Abstract/Free Full Text]
18. Roth J.A., Atkinson E.N., Fossella F., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. Lung Cancer 1998;21:1-6.[Medline]
19. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non–small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-1892.[Abstract/Free Full Text]
20. Sugarbaker D.J., Herndon J., Kohman L.J., Krasna M.J., Green M.R. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non–small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995;109:473-485.[Abstract/Free Full Text]
21. Yashar J., Weitberg A.B., Glicksman A.S., Posner M.R., Feng W., Wanebo H.J. Preoperative chemotherapy and radiation therapy for stage IIIa carcinoma of the lung. Ann Thorac Surg 1992;53:445-448.[Abstract]
22. Sonnett J.R., Krasna M.J., Suntharalingam M., et al. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation. Ann Thorac Surg 1999;68:316-320.[Abstract/Free Full Text]
23. Marik P.E., Varon J. Severity scoring and outcome assessment. Crit Care Clin 1999;15:633-646.[Medline]
24. Sauaia A., Moore F.A., Moore E.E., Lezotte D.C. Early risk factors for postinjury multiple organ failure. World J Surg 1996;20:392-400.[Medline]
25. Daley J. Criteria by which to evaluate risk-adjusted outcomes programs in cardiac surgery. Ann Thorac Surg 1994;58:1827-1835.[Abstract]
26. Parsonnet V., Dean D., Bernstein A.D. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation 1989;79:1-3.[Abstract/Free Full Text]
27. Brunelli A., Fianchini A., Gesuita R., Carle F. POSSUM scoring system as an instrument of audit in lung resection surgery. Physiological and operative severity score for the enumeration of mortality and morbidity. Ann Thorac Surg 1999;67:329-331.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. W. Kim, L. P. Faber, W. H. Warren, S. Basu, S. C. Wightman, J. A. Weber, P. Bonomi, and M. J. Liptay Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann. Thorac. Surg., September 1, 2009; 88(3): 937 - 943. [Abstract] [Full Text] [PDF]

				A. Brunelli, A. Charloux, C. T. Bolliger, G. Rocco, J-P. Sculier, G. Varela, M. Licker, M. K. Ferguson, C. Faivre-Finn, R. M. Huber, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Eur. Respir. J., July 1, 2009; 34(1): 17 - 41. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, E. Gyllstedt, A. Pikwer, and P. Jonsson Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Ann. Thorac. Surg., August 1, 2008; 86(2): 376 - 382. [Abstract] [Full Text] [PDF]

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 181 - 185. [Abstract] [Full Text] [PDF]

				R. P. Petersen, D. Pham, E. M. Toloza, W. R. Burfeind, D. H. Harpole Jr, S. I. Hanish, and T. A. D'Amico Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. Ann. Thorac. Surg., July 1, 2006; 82(1): 214 - 218. [Abstract] [Full Text] [PDF]

				A. Brunelli, F. Xiume', M. Al Refai, M. Salati, R. Marasco, and A. Sabbatini Gemcitabine-Cisplatin Chemotherapy Before Lung Resection: A Case-Matched Analysis of Early Outcome Ann. Thorac. Surg., June 1, 2006; 81(6): 1963 - 1968. [Abstract] [Full Text] [PDF]

				O. Schussler, M. Alifano, H. Dermine, S. Strano, A. Casetta, S. Sepulveda, A. Chafik, S. Coignard, A. Rabbat, and J.-F. Regnard Postoperative Pneumonia after Major Lung Resection Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1161 - 1169. [Abstract] [Full Text] [PDF]

				B. F. Meyers, F. Haddad, B. A. Siegel, J. B. Zoole, R. J. Battafarano, N. Veeramachaneni, J. D. Cooper, and G. A. Patterson Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 822 - 829. [Abstract] [Full Text] [PDF]

				Y. Matsubara, S.-i. Takeda, and T. Mashimo Risk Stratification for Lung Cancer Surgery: Impact of Induction Therapy and Extended Resection Chest, November 1, 2005; 128(5): 3519 - 3525. [Abstract] [Full Text] [PDF]

				P. Van Schil, J. Van Meerbeeck, G. Kramer, T. Splinter, C. Legrand, G. Giaccone, C. Manegold, and N. van Zandwijk Morbidity and mortality in the surgery arm of EORTC 08941 trial Eur. Respir. J., August 1, 2005; 26(2): 192 - 197. [Abstract] [Full Text] [PDF]

				I. S. Choi, D.-Y. Oh, J. H. Kwon, S.-I. Kim, S. R. Park, J.-Y. Bak, J. H. Kim, D.-W. Kim, Y. T. Kim, T.-Y. Kim, et al. Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 6 - 12. [Abstract] [Full Text] [PDF]

				K. P. Grichnik and T. A. D'Amico Acute Lung Injury and Acute Respiratory Distress Syndrome After Pulmonary Resection Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 317 - 334. [Abstract] [PDF]

				S. Endo, Y. Sato, T. Hasegawa, K. Tetsuka, S. Otani, N. Saito, Y. Tezuka, and Y. Sohara Preoperative chemotherapy increases cytokine production after lung cancer surgery Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 787 - 791. [Abstract] [Full Text] [PDF]

				D. C. Betticher, S.-F. Hsu Schmitz, M. Totsch, E. Hansen, C. Joss, C. von Briel, R. A. Schmid, M. Pless, J. Habicht, A. D. Roth, et al. Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non-Small-Cell Lung Cancer: A Multicenter Phase II Trial J. Clin. Oncol., May 1, 2003; 21(9): 1752 - 1759. [Abstract] [Full Text] [PDF]

				M. Ohta, N. Sawabata, H. Maeda, and H. Matsuda Efficacy and safety of tracheobronchoplasty after induction therapy for locally advanced lung cancer J. Thorac. Cardiovasc. Surg., January 1, 2003; 125(1): 96 - 100. [Abstract] [Full Text] [PDF]

				W. J. Scott, J. Howington, and B. Movsas Treatment of Stage II Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 188S - 201S. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				A. A. Vaporciyan, K. W. Merriman, F. Ece, J. A. Roth, W. R. Smythe, S. G. Swisher, G. L. Walsh, J. C. Nesbitt, and J. B. Putnam Jr Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation Ann. Thorac. Surg., February 1, 2002; 73(2): 420 - 426. [Abstract] [Full Text] [PDF]

				N. Novoa, G. Varela, and M.F. Jimenez Morbidity after surgery for non-small cell lung carcinoma is not related to neoadjuvant chemotherapy Eur. J. Cardiothorac. Surg., October 1, 2001; 20(4): 700 - 704. [Abstract] [Full Text] [PDF]

				J. B. Putnam Jr The anatomic basis for lung cancer staging: the end of the beginning? Ann. Thorac. Surg., June 1, 2001; 71(6): 1757 - 1758. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael P. Siegenthaler Jack A. Roth Stephen G. Swisher Garrett L. Walsh Ara A. Vaporciyan W. Roy Smythe Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegenthaler, M. P. Articles by Putnam, J. B. Search for Related Content PubMed PubMed Citation Articles by Siegenthaler, M. P. Articles by Putnam, J. B., Jr Related Collections Lung - cancer